

Of mice and men in ACM

Citation for published version (APA):

Colpaert, R. M. W. (2023). Of mice and men in ACM: novel models and biomarkers for arrhythmogenic cardiomyopathy. [Doctoral Thesis, Maastricht University]. Maastricht University. https://doi.org/10.26481/dis.20230907rc

Document status and date: Published: 01/01/2023

DOI: 10.26481/dis.20230907rc

Document Version: Publisher's PDF, also known as Version of record

Please check the document version of this publication:

 A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.

• The final author version and the galley proof are versions of the publication after peer review.

 The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these riahts.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
 You may not further distribute the material or use it for any profit-making activity or commercial gain
 You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Summary

Arrhythmogenic cardiomyopathy (ACM) is a genetically inherited heart disease characterized by progressive fibro-fatty replacement of the myocardium leading to ventricular arrhythmias and sudden death in patients. Endurance exercise can initiate or exacerbate disease progression, making early and reliable diagnosis vital. Genetically, ACM is very heterogenous, with at least 16 linked genes, most of them related to the intercalated disc and especially the desmosome. Currently, there are no real curative treatments for ACM, stemming in part from the lack of insight into what molecular mechanisms drive the disease.

To answer this need, in **chapter 2** we describe two mouse models carrying the p.Q563* *Dsg2* nonsense mutation in hetero- ($Dsg2^{KI/WT}$) or homozygosity ($Dsg2^{KI/KI}$) as well as a human induced pluripotent stem cell cardiomyocyte (hiPSC-CM) model carrying the homologous p.Q558* DSG2 nonsense mutation found in an ACM patient. We found that the $Dsg2^{KI/WT}$ mice had a very attenuated phenotype without clear signs of ACM, however the $Dsg2^{KI/KI}$ mice had a strong ACM-like phenotype with fibrosis and possible wall thinning in the right ventricle. Structural and functional measures became worse with age and following an exercise regimen. Meanwhile for the *in vitro* models, multiple components of the intercalated disc were dysregulated for the mutant hiPSC-CMs compared to isogenic controls we created. Comparing the results of RNA sequencing on all three models, we found that there were multiple transcriptional overlaps between the models, pointing towards commonly perturbed pathways.

In **chapter 3** we follow this up with the characterization of two more models, consisting of a murine line and a hiPSC-CM model both carrying the heterozygous p.R79* PKP2 mutation. Here we found that, while neither model showed strong ACM hallmarks, in mice, the cardiac desmosomes were affected and the cardiomyocytes were more susceptible to conditions of increased stress.

In addition to the lack of therapies, diagnosis of ACM is cumbersome, based on a set of major and minor criteria in six different categories. To answer this need for improved screening tools, in **chapters 4 and 5** we elaborate on the role of miRNAs and other epigenetic regulators in cardiovascular disease, after which in **chapter 6** we discuss miR-185-5p as a potential new circulating miRNA-based ACM biomarker.

In conclusion, the murine and hiPSC-CM ACM models we have characterized will help to deepen our fundamental understanding of the disease and can serve as testbeds for novel therapies, while the biomarker we have identified holds potential for the diagnosis of ACM.